Introduction
============

Intervertebral disc degeneration (IDD) is considered to be one of the strongly associated causes of lower back pain and related diseases of the spine, which exert a high cost on society \[[@B1],[@B2]\]. It is well known, however, that the intervertebral disc is an avascular tissue that has limited capacity for regeneration. This has prompted research to improve our understanding of the biology of intervertebral disc healing and into methods to enhance the regenerative process. Recently, biological treatments for early intervention have been introduced and developed, including the application of active substances, gene therapy and tissue engineering based on stem cells. These treatments have been reported to promote intervertebral disc regeneration by upregulating the synthesis of extracellular matrix and the metabolism of the intervertebral discs, further shedding light on the reversal and repair of IDD \[[@B3],[@B4]\].

The most direct therapeutic strategy for reversing IDD is the injection of active substances, mainly including multiple biologically active growth factors. As it contains high concentrations of platelets, which can release various kinds of multifunctional growth factors when activated (Table [1](#T1){ref-type="table"}), platelet-rich plasma (PRP) represents a new strategy for the biological treatment of IDD \[[@B5]\]. Current studies have indicated that a variety of cytokines applied in the early stage of IDD could lead to a good outcome, as a large number of phenotypically stable cells are still present and could still react to these cytokines in the early degenerated discs. In addition, the combined application of multiple cytokines released from PRP will contribute to synergistic effects. This review explores the current biological therapeutic strategies for IDD and PRP as an autologous blood product used in the treatment of IDD. This survey and discussion might serve as a source of information to aid future applications of PRP and the design of appropriate biological strategies for treating human IDD.

###### 

Growth factors identified within platelet-rich plasma and their biological functions

  **Name**                             **Abbreviation**   **Function**
  ------------------------------------ ------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Platelet-derived growth factor       PDGF               Stimulation of fibroblast production, chemotaxis, transforming growth factor-β1, collagen production; upregulation of proteoglycan synthesis of fibroblasts, smooth muscle cells, chondrocytes, osteoblasts and mesenchymal stem cells
  Insulin-like growth factor-1         IGF1               Promotion of cell growth, differentiation, recruitment in bone, blood vessel, skin, other tissues; upregulation of collagen synthesis with PDGF of fibroblasts
  Transforming growth factor-beta 1    TGF-β1             Promotion of fibroblast proliferation, extracellular matrix formation, cell viability, production of collagen from fibroblasts; suppressed interleukin 1-mediated effects on proteoglycan synthesis in cartilage
  Vascular endothelial growth factor   VEGF               Promotion of cell growth, migration, new blood vessel growth and anti-apoptosis (anti-cell death) of blood vessel cells
  Basic fibroblastic growth factor     bFGF               Stimulation of collagen production, angiogenesis and myoblast proliferation
  Epidermal growth factor              EGF                Promotion of cell recruitment, proliferation, differentiation, angiogenesis, cytokine secretion by mesenchymal and epithelial cells
  Connective tissue growth factor      CTGF               Promotion of angiogenesis, cartilage regeneration, fibrosis, platelet adhesion

In view of the multiple biologically active growth factors stored in platelets, the table presents a broad but also far from complete view of the effects of the growth factors.

What is intervertebral disc degeneration?
-----------------------------------------

IDD is perhaps best defined as a cascade that begins with changes to the cellular microenvironment and progresses to the structural breakdown and functional impairment of the intervertebral disc \[[@B6]\]. Aging, living conditions, biomechanical loading and genetic factors are often related to disc degeneration \[[@B7],[@B8]\]. Prominent changes occurring during IDD are characterized by a decrease of active cell numbers, depletion of extracellular matrix, altered phenotype of normal disc cells, and the presence of pro-inflammatory cytokines and mediators \[[@B9],[@B10]\]. These cellular and molecular changes greatly influence the progression of IDD, which further impairs the biological and mechanical function of the intervertebral disc and patients' quality of life.

Current clinical treatments for intervertebral disc degeneration and their limitations
--------------------------------------------------------------------------------------

Current therapeutic strategies for treating IDD are primarily conservative, including physiotherapy and anti-inflammatory medications. Spinal surgery, mainly including discectomy, interbody fusion and disc replacement, are the current gold standard to alleviate symptoms of IDD, but the adjacent spine may experience a high risk of accelerated degeneration \[[@B11]\]. Therefore, the choice of an effective treatment for IDD with minimal adverse effects on individuals is particularly important to prevent the degenerative trend of IDD and relieve pain in patients.

Current status of biological treatments for intervertebral disc degeneration
----------------------------------------------------------------------------

With our improving understanding of the importance of the molecular and cellular mechanisms of IDD, biological treatments are attracting more attention \[[@B12],[@B13]\]. Promising biological treatments predominantly consist of direct injection of active substances, gene therapy and tissue engineering based on certain cells.

Direct injection of active substances could stimulate the proliferation of intervertebral disc cells and the accumulation of extracellular matrix \[[@B14]\], which could slow or even reverse the degenerative trend of IDD. However, the short half-life of active substances hinders the effectiveness of this therapy. So the ideal approach is to transfect intervertebral disc cells with genes encoding the active proteins so that these cells could stably produce the corresponding bioactive products, thus upregulating the synthesis of extracellular matrix in a gradual way. Tissue engineering using cells, especially stem cells, is based on the fact that the increase in active cells within the intervertebral disc will gradually restore its structural integrity and function; many studies have confirmed the efficacy of this procedure \[[@B15]-[@B17]\]. Carriers or scaffolds of stem cells with good bio-compatibility are currently being developed with promising prospects.

However, studies on biological treatments for IDD have so far mostly been restricted to *in vitro* studies and animal experiments, and clinical application is still a long way in the future. According to current experimental results, biological treatments hold broad prospects for preventing or even reversing the progression of IDD.

Biological and pathological characteristics of intervertebral disc degeneration: the importance of and opportunities for early interventions
--------------------------------------------------------------------------------------------------------------------------------------------

With the lack of nutrient diffusion through the cartilaginous endplate, degenerated intervertebral discs may undergo a gradual decrease in active cell numbers \[[@B18]\]. Also, the degenerative process of the intervertebral disc is significantly related to the loss of proteoglycan, which further lowers the osmotic pressure of the internal environment and renders the degenerated disc unable to maintain hydration under load \[[@B19]\]. Although collagen content decreases with the progression of IDD, this is not significant compared to that of proteoglycans. However, a shift in the balance of collagen types and their distribution may occur. The decrease in collagen content and the shift from type II to type I collagen contribute to fibrosis of the nucleus pulpous \[[@B20]\]. With the fusion of the nucleus pulposus and annulus fibrosis, the difference between the two becomes less obvious.

IDD is a progressive, chronic disease. Over time, the degeneration worsens and ultimately becomes irreversible, so early biological intervention is important to reverse the trend of degeneration \[[@B21]\]. In the late stage of IDD, the calcified cartilage endplates (CEPs) hold limited potential for vascularization and nutrient delivery. Early intervention during disc degeneration has many advantages because many viable cells are still retained and cellular phenotypic changes are few. So the injection of active substances is potent enough to stimulate restoration during the early stage of degeneration. Early in IDD, single or multiple injections of biologically active substances, especially growth factors, could effectively regulate the metabolic balance of the extracellular matrix and maintain the homeostasis of the intervertebral disc \[[@B22]\]. Gene therapy \[[@B23],[@B24]\] and tissue engineering based on stem cells \[[@B25],[@B26]\] are possible alternative choices for IDD therapy. Gene therapy could prolong the duration of expression of active substances but the efficacy of clinical application and safety issues have not yet been determined. Tissue engineering based on cells requires a high standard of clinical research, complicated culture conditions, as well as complex surgical procedures. Meanwhile, the existence of immune rejection, tumorigenicity of the transplanted cells, and unexpected outcomes restrict the prospects for their clinical application. Therefore, the ideal solution to prevent or even reverse the degenerative trend of IDD is intervention using active substances in the early stage of IDD.

Effects of platelet-rich plasma growth factors on intervertebral disc degeneration: *in vitro* and *in vivo* studies
--------------------------------------------------------------------------------------------------------------------

The injection of active substances is more suitable for early intervention in IDD compared with other therapies. Stimulation from active substances, especially the cytokines or growth factors present in PRP, maintains intervertebral disc homeostasis by shifting cellular catabolism to the anabolic state \[[@B27]\]. The clinical injection of active substances can be carried out under fluoroscopic guidance and is less invasive than spinal surgeries, especially for multi-segment disc degeneration, reducing injury to a minimum level.

Many *in vivo* and *in vitro* studies have been conducted using multiple growth factors present in PRP to stimulate the proliferation of intervertebral disc cells with promising results (Table [2](#T2){ref-type="table"}). Transforming growth factor (TGF)-β1 is one of the early morphogenic molecules studied *in vitro* to promote the synthesis of proteoglycans \[[@B28],[@B29]\]. Gruber and colleagues \[[@B30]\] reported that TGF-β1 could effectively stimulate the proliferation of human annulus fibrosus cells after 4 days exposure. Lee and colleagues \[[@B31]\] confirmed the proliferative effect of TGF-β1 when culturing rabbit nucleus pulposus cells seeded in atelocollagen scaffolds under the stimulation of TGF-β1. Insulin-like growth factor (IGF)-1 has a similar function as it promotes cell proliferation and matrix synthesis *in vitro*\[[@B32]\]. A study from Hayes and Ralphs \[[@B33]\] confirmed that TGF-β1 and IGF-1, both alone and in combination, could effectively stimulate the synthesis of sulfated glycosaminoglycan and collagen types I and II by annulus cells. Further, these authors proved the potential role of TGF-1 in pushing cells towards a fibrocartilaginous phenotype, with possible complementary effects of IGF-1. In addition, IGF-1 and platelet-derived growth factor (PDGF) were both reported to be able to reduce the percentage of apoptotic annulus fibrosus cells \[[@B34]\]. However, another study indicated that TGF-β was superior to epidermal growth factor (EGF), IGF-1, PDGF and fibroblastic growth factor (FGF) in upregulating the synthesis of proteoglycan \[[@B32]\].

###### 

**The*in vitro*and*in vivo*influence of growth factors present in platelet-rich plasma**

  **Growth factor**   **Dose**           **Species**                             **Target cell type/tissue/animal model**                **Cellular scaffold**   **Outcome**                                                                                                                                                                             **Study**                           **Year**
  ------------------- ------------------ --------------------------------------- ------------------------------------------------------- ----------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------- ----------
  *In vitro*                                                                                                                                                                                                                                                                                                                                                                                     
  PDGF                100 ng/ml          Human                                   Annulus fibrosus cells                                  None                    Significant reduction in the percentage of apoptotic cells                                                                                                                              Gruber *et al.*\[[@B30]\]             1997
                      1-20 ng/ml         Bovine                                  Coccygeal nucleus pulposus and annulus fibrosus cells   None                    Improved proliferation                                                                                                                                                                  Pratsinis and Kletsas \[[@B35]\]      2007
  IGF1                20 ng/ml           Mature canine                           Intervertebral disc tissues                             None                    Increased matrix synthesis and cell proliferation                                                                                                                                       Thompson *et al.*\[[@B32]\]           1991
                      1-1,000 ng/ml      Bovine                                  Nucleus pulposus cells                                  None                    Increased proteoglycan synthesis                                                                                                                                                        Osada *et al.*\[[@B29]\]              1996
                      20-500 ng/ml       Human                                   Annulus fibrosus cells                                  None                    Significant reduction in the percentage of apoptotic cells                                                                                                                              Gruber *et al.*\[[@B34]\]             2000
                      5-200 ng/ml        Bovine                                  Coccygeal nucleus pulposus and annulus fibrosus cells   None                    Improved proliferation                                                                                                                                                                  Pratsinis and Kletsas \[[@B35]\]      2007
                      5 ng/ml            E19 rat                                 Annulus fibrosus cells                                  None                    Upregulation of extracellular matrix                                                                                                                                                    Hayes *et al.*\[[@B33]\]              2011
  TGF-β1              1 ng/ml            Mature canine                           Intervertebral disc tissues                             None                    Increased matrix synthesis and cell proliferation                                                                                                                                       Thompson *et al.*\[[@B32]\]           1991
                      5 ng/ml            E19 rat                                 Annulus fibrosus cells                                  None                    Pushed cells towards a fibrocartilaginous phenotype                                                                                                                                     Hayes and Ralphs \[[@B33]\]           2011
                      10 ng/ml           Rabbit                                  Nucleus pulposus cells                                  Atelocollagen           Robust refurbishment of matrix                                                                                                                                                          Lee *et al.*\[[@B31]\]                2012
  VEGF                Not mentioned      Vegfr-1lacZ/+ and Vegfr-2lacZ/+ mouse   Nucleus pulposus cells                                  None                    Promotion of nucleus pulposus survival                                                                                                                                                  Fujita *et al.*\[[@B36]\]             2008
  bFGF                300 ng/ml          Mature canine                           Intervertebral disc tissues                             None                    Increased matrix synthesis and cell proliferation                                                                                                                                       Thompson *et al.*\[[@B32]\]           1991
                      0.1-20 ng/ml       Bovine                                  Coccygeal nucleus pulposus and annulus fibrosus cells   None                    Enhanced proliferation                                                                                                                                                                  Pratsinis and Kletsas \[[@B35]\]      2007
  EGF                 1 ng/ml            Mature canine                           Intervertebral disc tissues                             None                    Enhanced proliferation                                                                                                                                                                  Thompson *et al.*\[[@B32]\]           1991
  CTGF                Not mentioned      Rhesus monkey                           Lumbar intervertebral disc nucleus pulposus cells       None                    Enhanced synthesis of proteoglycan and collagen II                                                                                                                                      Liu *et al.*\[[@B37]\]                2010
  *In vivo*                                                                                                                                                                                                                                                                                                                                                                                      
  IGF1                8 ng/8 ul/disc     Male Swiss Webster mouse                Caudal disc compression model                           None                    An upward trend of cell density, but not statistically significant (single injection); a trend of increased disc height, but also not statistically significant (multiple injections)   Walsh *et al.*\[[@B38]\]              2004
  TGF-β1              1.6 ng/8 μl/disc   Male Swiss Webster mouse                Caudal disc compression model                           None                    A greater percentage of proliferating cells, but not statistically significant (single injection); increased population of anular fibrochondrocytes (multiple injections)               Walsh *et al.*\[[@B38]\]              2004
  bFGF                8 ng/8 μl/disc     Male Swiss Webster mouse                Caudal disc compression model                           None                    An upward trend of cell density, but not statistically significant (single injection)                                                                                                   Walsh *et al.*\[[@B38]\]              2004

The growth factors listed are stored in platelets and have exhibited promising potential in the regeneration of degenerated discs, indicating the potential of platelet-rich plasma therapy. *bFGF*, basic fibroblastic growth factor; *CTGF*, connective tissue growth factor; *EGF*, epidermal growth factor; *GDF*, growth and differentiation factor; *IGF*, insulin-like growth factor; *PDGF*, platelet-derived growth factor; *TGF*, transforming growth factor; *VEGF*, vascular endothelial growth factor.

In an *in vitro* culture system, Pratsinis and Kletsas \[[@B35]\] reported that PDGF, basic FGF (bFGF) and IGF-I could all effectively stimulate the proliferation of intervertebral disc cells obtained from bovine coccygeal tissues, and PDGF was the most potent mitogen among these. Vascular endothelial growth factor (VEGF)-A functions in nucleus pulposus survival as it has strong angiogenic activity and specific mitogenic and chemotactic actions \[[@B36]\]. In a gene transfection study, Liu and colleagues \[[@B37]\] reported that the increased connective tissue growth factor (CTGF) expression resulting from transfecting rAAV2-CTGF into Rhesus monkey lumbar nucleus pulposus cells enhanced collagen type II protein and proteoglycan synthesis. In a degenerative murine caudal disc compression model, Walsh and colleagues \[[@B38]\] compared the effects of single and multiple injections of a variety of growth factors, including growth and differentiation factor (GDF)-5, TGF-β, IGF-1, and bFGF; GDF-5 and TGF-β induced the expansion of the inner annulus fibrosus fibrochondrocyte populations into the nucleus pulposus and upregulated the expression of aggrecan and type II collagen, while IGF-1 yielded a transient proliferative effect. The authors thus concluded that early intervention during disc degeneration had implications for the arrest or slowing of the degenerative process.

Given the interactions of growth factors that are necessary for proper intervertebral disc homeostasis and regeneration, it is unlikely that any single growth factor will alone enable the repair of IDD, but rather a combination of multiple growth factors will be needed. Based on the concept that a combination approach is necessary for disc regeneration, recent attention has turned to PRP.

Platelet-rich plasma as a strategy for intervertebral disc degeneration repair and regeneration
-----------------------------------------------------------------------------------------------

PRP can be defined as a volume of autologous plasma with the platelet concentration above baseline \[[@B39]\]. PRP has been clinically applied for its healing properties \[[@B40]\], and now is widely applied in many therapeutic areas. The concept that PRP application would promote IDD regeneration is based on the role of platelets in wound healing. When activated, platelets can secrete a variety of growth factors, including PDGF, IGF-1, TGF-β, VEGF, bFGF, EGF, and CTGF, among others \[[@B41],[@B42]\]. All these growth factors might play significant roles in promoting the proliferation of tissues. Platelets also contain antibacterial and bactericidal proteins that may influence the process of inflammatory responses by inducing the synthesis of some molecules, such as integrins, interleukins and chemokines \[[@B43]\]. Last but not least, platelets may serve as a biological sponge because they can absorb, store and transfer some small molecules that regulate tissue regeneration \[[@B44]\]. PRP represents a new biotechnology in tissue engineering and has become a popular clinical treatment for various tissue healing applications without any immune rejections.

Compared with other bioactive peptides or growth factors, however, PRP is limited in its clinical application mainly because of its autologous origin. If the physical condition of a patient renders them unsuitable for generating PRP, such as patients with hematologic diseases, then PRP will not be an ideal therapy for IDD. Modern biotechnology has greatly increased our knowledge about the gene sequences and receptors of many bioactive substances and although artificially synthesized growth factors are more costly with short half-lives, they are convenient and their application is not restrained by the physical condition of the patient.

Compared with other bioactive factors, PRP is rather a good choice for patients qualified for PRP preparations. Unlike other bioactive factors with complicated or unstable properties used for the clinical treatment of damaged tissues, PRP can be quickly obtained in the operating room by centrifugation of the patient's own blood and directly applied to target tissues. Also, from the viewpoint of clinical application, autologous PRP avoids complex regulations, disease transmission and immunologic reactions \[[@B45]\].

PRP injection into degenerated intervertebral discs is currently a relatively less invasive and convenient therapeutic procedure compared to other options. However, needle puncture could induce cell death and degeneration of discs \[[@B46]-[@B48]\], so needles of smaller size and the fewest numbers of injections possible are beneficial for clinical patients. To the best of our knowledge, no clinical studies have so far indicated the number of injections required. Some preclinical studies have indicated that a single injection of PRP in the degenerated discs of animal models was effective to help restore disc height and water content \[[@B46]-[@B48]\]. Gullung and colleagues \[[@B46]\] confirmed that a single injection of PRP into the degenerated discs of Sprague--Dawley rats was effective for maintaining fluid content on magnetic resonance imaging (MRI). Obata and colleagues \[[@B47],[@B48]\] proved that a single intra-discal injection of PRP serum was potent enough to restore disc height and induce cell proliferation in a rabbit IDD model. In our previous animal study, which established an early IDD model, a single injection of PRP was effective for IDD regeneration \[[@B49]\].

Considering these animal studies, we propose that a single injection using smaller needles at the right time, especially in the early stage of IDD, might be sufficient for clinical applications. However, more clinical studies are needed in the future to confirm this.

Current evidence for the efficacy of platelet-rich plasma therapy in intervertebral disc degeneration
-----------------------------------------------------------------------------------------------------

PRP contains a variety of proteins and growth factors that are expected to serve as a therapeutic growth factor cocktail, playing a pivotal role in regulating the tissue microenvironment, improving cellular functions and promoting the regeneration of damaged tissues. Many *in vivo* and *in vitro* studies have confirmed the efficacy of PRP in IDD treatment (Table [3](#T3){ref-type="table"}).

###### 

***In vitro*and*in vivo*effects of platelet-rich plasma on intervertebral disc regeneration**

  **Activator**                                                       **System used to obtain PRP**                                              **Cell scaffold**   **PRP carriers**                **Results**                                                                                                                       **Authors**                         **Year**
  ------------------------------------------------------------------- -------------------------------------------------------------------------- ------------------- ------------------------------- --------------------------------------------------------------------------------------------------------------------------------- --------------------------------- ------------
  10% thrombin solution (vol/vol, 1,000 U/ml in 100 mmol/l CaCl~2~)   SYMPHONY 2 Platelet Concentration System (DePuy Spine, Raynham, MA, USA)   Alginate beads      None                            Increased accumulation of glycosaminoglycan; upregulated mRNA expression of Sox9, type II collagen, and aggrecan                  Akeda *et al.*\[[@B52]\]              2006
  Bovine thrombin (100 IU bovine thrombin/150 ml PRP)                 MSC blood cell separation system (Haemonetics Corp., Braintree, MA, USA)   None                None                            Induction of human nucleus pulposus proliferation and chondrogenic differentiation                                                Chen *et al.*\[[@B50]\]               2006
  Not stated                                                          Two centrifugation techniques                                              None                Gelatin hydrogel microspheres   Less severe histological grading scale and increased proteoglycan production                                                      Nagae *et al.*\[[@B53]\]              2007
  Bovine thrombin (100 IU bovine thrombin/150 ml PRP)                 MSC blood cell separation system (Haemonetics Corp.)                       None                None                            Significantly increased levels of mRNAs involved in chondrogenesis and matrix accumulation; increased disc height index           Chen *et al.*\[[@B51]\]               2009
  Not stated                                                          Two centrifugation techniques                                              None                Gelatin hydrogel microspheres   Increased mRNA expression of proteoglycan core protein and type II collagen; maintained disc height and signal intensity on MRI   Sawamura *et al.*\[[@B54]\]           2009
  Not stated                                                          Not stated                                                                 None                None                            Higher fluid content on MRI, reversed or modified disc height                                                                     Gullung *et al.*\[[@B46]\]            2011
  Autologous serum and 2% CaCl~2~                                     Two centrifugation techniques                                              None                None                            Restored disc height and stimulated MRI T2 value                                                                                  Obata *et al.*\[[@B47],[@B48]\]    2010, 2012
  10% thrombin solution (vol/vol, 1,000 U/ml in 90 mmol/l CaCl~2~)    Two centrifugation techniques                                              None                None                            Increased production of extracellular matrix and maintained MRI signal intensity                                                  Hu *et al.*\[[@B49]\]                 2012

The efficacy of PRP has been confirmed by many *in vivo* and *in vitro* studies, working via the proliferative effects of multiple growth factors secreted from the platelets. PRP could effectively stimulate the restoration of degenerated discs by promoting cell proliferation and increasing the production of extracellular matrix. *MRI*, magnetic resonance imaging; *MSC*, mesenchymal stem cell; *PRP*, platelet-rich plasma.

Chen and colleagues \[[@B50]\] demonstrated that PRP might be a therapeutic candidate for the prevention of IDD by culturing intervertebral disc cells together with PRP. Subsequently, Chen and colleagues \[[@B51]\] introduced a novel intervertebral disc organ culture system to study a PRP-based therapeutic approach for the amelioration of IDD. Their results indicated that PRP could promote nucleus pulposus regeneration and resulted in significantly increased levels of mRNAs involved in chondrogenesis and matrix accumulation; moreover, the disc height index was significantly increased in the PRP regeneration groups.

A study from Akeda and colleagues \[[@B52]\] demonstrated that PRP had a mild stimulatory effect on the proliferation of intervertebral disc cells. The authors concluded that the local administration of PRP might stimulate intervertebral disc repair, and autologous blood would be favored as a source of growth factors needed to stimulate cells for tissue engineering of the intervertebral disc. However, the injected PRP within intervertebral discs might release growth factors in an unstable manner at different rates. To slow the release of biological factors within PRP, Nagae and colleagues \[[@B53]\] used a combination therapy of PRP implanted within gelatin hydrogel microspheres on a rabbit IDD model. The immobilized PRP released PRP-related growth factors in a sustained manner with the degradation of the microspheres, and the degeneration of intervertebral discs was remarkably suppressed over the 8-week period in the PRP group. The authors suggested that the combined administration of PRP and gelatin hydrogel microspheres may serve as a promising therapeutic strategy for IDD. This study was advanced by Sawamura and colleagues \[[@B54]\], the authors further confirming the efficacy of PRP impregnated within gelatin hydrogel microspheres to retard the degenerative trend. Gullung and colleagues \[[@B46]\] compared the regenerative effects of early PRP injection and delayed PRP injection in a rat IDD model induced by needle puncture of Sprague--Dawley rats. Both early and delayed PRP intervention resulted in higher fluid content on MRI, and the disc was superior in the early PRP injection group. Obata and colleagues \[[@B47],[@B48]\] demonstrated that intra-discal injection of PRP serum was effective for restoring disc height and promoting cell proliferation in a rabbit model, and further held that PRP is safe and immediately available for clinical application. Recently, a study from our group confirmed that a single injection of PRP was potent enough to increase the production of extracellular matrix and maintained the MRI signal intensity of degenerated discs in a rabbit model \[[@B49]\]. All these studies offer a promising option for the regeneration of IDD compared with the traditional, conservative therapies and ultimate surgery, and indicate that PRP could effectively stimulate the restoration of degenerated intervertebral discs via the proliferative effects of multiple growth factors secreted from the platelets.

Possible mechanism of the therapeutic effect of platelet-rich plasma in intervertebral disc degeneration
--------------------------------------------------------------------------------------------------------

Platelets have exhibited greater therapeutic potential than ever imagined, releasing growth factors and other molecules that help to repair damaged tissues \[[@B55]\]. Over 1,500 proteins are stored within platelets, including growth factors in platelet α-granules that have been proven to promote normal healing responses \[[@B56],[@B57]\]. PRP, as a source of concentrated platelets, may help to restore the integrity of the cellular matrix of degenerating discs through the synergistic effects of multiple growth factors.

The balance between decomposition and accumulation determines the integrity and mechanical behavior of discs. Thus, increased extracellular matrix, mainly including aggrecan and collagen, helps to maintain the mechanical functions of the discs. Aggrecan, the major proteoglycan, is rich in negatively charged sulfate and carboxyl groups, contributing to high osmotic pressure for the absorption of water \[[@B19],[@B58],[@B59]\]. The increased collagen provides tensile strength and anchors the tissue to the bone \[[@B19]\].

As an aneural and avascular tissue, the intervertebral disc derives nutrients and oxygen from two thin CEPs \[[@B60]\]. During the progression of IDD, the calcification of the CEPs is accompanied by the obliteration of the small blood vessels \[[@B61]\]. This was supposed to be one of the causes of IDD. In degenerating discs, however, blood vessels were found in the endplates and subchondral bone, which may imply that vascularization was strongly associated with tissue repair \[[@B62],[@B63]\]. Based on this understanding, VEGF released from PRP is a potent cytokine for vascularization within the CEP, promoting the diffusion of nutrients to the degenerated discs. The synthesis of integrins and interleukins induced by the platelets will spark the inflammatory response and alert immune cells \[[@B43],[@B44]\]. As the apoptosis of chondrocytes within the CEP is believed to be an important cause of IDD, PRP-derived growth factors, such as TGF-β, IGF, and FGF may restore the degenerated CEP by promoting cell growth and tissue regeneration.

Although new vessel formation would help to re-establish nutritive perfusion during the process of wound healing \[[@B64],[@B65]\], the enhanced neovascularization is associated with severe histodegeneration of the discs. Also, the local vascular inflammatory reactions resulting from the synthesis of integrins and interleukins may be the main cause of the painful disc fibrosis and degeneration \[[@B66]\]. Degeneration in discs is associated with increases in the number of nerves and blood vessels \[[@B67]\]. Thus, along with the advantage of better nutrient supply induced by PRP, there is the possible disadvantage of significant pain and calcification through the process of inflammation. Therefore, further studies are still needed to investigate the undesirable effects induced by PRP.

Some studies have indicated that a certain number of mesenchymal stem cells (MSCs) exist in human degenerated intervertebral discs, including the CEP, nucleus pulposus and annulus fibrosus tissues \[[@B68]-[@B71]\], although none reported whether PRP affects the proliferation and differentiation of these specialized MSCs. But a study on the influence of PRP on human MSCs has proved that PRP enhanced MSC proliferation and induced chondrogenic differentiation of MSCs *in vitro*\[[@B72]\]. Stem cells derived from tendon also showed a trend to proliferate and differentiate toward activated tenocytes when cultured with PRP \[[@B73]\]. Therefore, we further propose that PRP, as a growth factor cocktail, might stimulate the differentiation of intervertebral disc MSCs towards mature intervertebral disc cells and upregulate the synthesis of extracellular matrix, and finally slow or reverse the degenerative trend of IDD.

Limitations of the current evidence on the application of platelet-rich plasma therapy and directions of future research
------------------------------------------------------------------------------------------------------------------------

PRP has demonstrated efficacy when used as a culture supplement for tissue engineering, as well as in promoting the biological regeneration of degenerated intervertebral discs. Currently, most findings indicate that PRP could serve as a potential therapeutic candidate to facilitate biological disc repair. However, some problems need to be resolved before the clinical application of PRP for the treatment of IDD. Currently, the pathological mechanism of IDD is still unclear, and current studies further indicate that a certain number of MSCs inhabit degenerated human nucleus pulposus. So, further studies are required to clarify the impact of PRP on the proliferation and differentiation of the nucleus pulposus-derived stem cells. PRP produced by different procedures may lead to varying degrees of platelet destruction, resulting in different concentrations of growth factors. Furthermore, as no uniform standard has been determined for stable PRP production, quality assurance of PRP should be taken into serious consideration. In addition, the optimal doses of various growth factors in PRP for tissue regeneration and the interactions between the different growth factors remain to be elucidated. Clinical PRP applications are currently focused on maxillofacial tissue engineering while clinical data for PRP therapy in IDD are still insufficient. The mechanism of IDD together with the roles of PRP in treating it are focal points of future research.
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